title: Malignant fibrous histiocytoma is a rare Lynch syndrome-associated tumor in two German families.
abstract: Lynch syndrome is characterized by germline mutations of the DNA mismatch repair genes MLH1 and MSH2. The tumor spectrum includes early onset colorectal, urogenital and other cancers. Soft tissue sarcomas have been anecdotally reported in patients with Lynch syndrome, but coincidental manifestation could not be excluded. In this report, we screened a cohort of Lynch syndrome families for tumors outside the established tumor spectrum. We identified two patients with Lynch syndrome and a malignant fibrous histiocytoma (MFH). In both families a causative MSH2 germline mutation (MSH2 c.2038C ≥ T or MSH2 c.942 ± 3A ≥ T) could be detected. Archival tumor material from both resected MFH was analyzed for microsatellite instability expression of MLH1 and MSH2. A mutator phenotype was detected in both MFH with loss of MSH2 protein expression. Subsequently, the causative MSH2 germline mutation was confirmed in both patients. Of note, both tumors were diagnosed at a local advanced stage but could be curatively resected 21 and 11 year ago, respectively. Both patients are alive without local or distant recurrence. In conclusion, our data further support that patients with Lynch syndrome are at increased risk for rare tumors such as MFH. However, the prognosis compared to sporadic MFH seems to be favorable.
authors: Medical Clinic 1, Biomedical Research Laboratory, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany. a.brieger@em.uni-frankfurt.de
authors: Angela
authors: A
authors: Brieger
authors: Knut
authors: K
authors: Engels
authors: Dieter
authors: D
authors: Schaefer
authors: Guido
authors: G
authors: Plotz
authors: Stefan
authors: S
authors: Zeuzem
authors: Jochen
authors: J
authors: Raedle
authors: Joerg
authors: J
authors: Trojan
references: Jpn J Clin Oncol. 1994 Jun;24(3):154-9
references: 8007425
references: J Med Genet. 2007 Jun;44(6):353-62
references: 17327285
references: Expert Rev Anticancer Ther. 2009 Aug;9(8):1135-44
references: 19671033
references: Cancer Res. 1994 Sep 1;54(17):4590-4
references: 8062247
references: Clin Cancer Res. 2009 Feb 1;15(3):762-9
references: 19188145
references: Histopathology. 2003 Sep;43(3):297-9
references: 12940783
references: Cancer. 1978 Jun;41(6):2250-66
references: 207408
references: Am J Gastroenterol. 2006 Jan;101(1):193-6
references: 16405554
references: Fam Cancer. 2011 Mar;10(1):37-42
references: 20872076
references: Ann Surg Oncol. 1998 Jun;5(4):356-60
references: 9641458
references: Cancer Res. 1995 Jan 15;55(2):242-8
references: 7812952
references: N Engl J Med. 2003 Mar 6;348(10):919-32
references: 12621137
references: J Med Genet. 2009 Jun;46(6):418-20
references: 19293170
references: Mutat Res. 2010 Nov 10;693(1-2):19-31
references: 19931546
references: J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
references: 14970275
references: Cancer Res. 2006 Aug 1;66(15):7810-7
references: 16885385
references: Clin Cancer Res. 2010 Apr 1;16(7):2214-24
references: 20215533
references: N Engl J Med. 2005 May 5;352(18):1851-60
references: 15872200
references: Fam Cancer. 2009;8(3):209-13
references: 19130300
references: Genes Chromosomes Cancer. 2000 Dec;29(4):353-5
references: 11066081
references: Ann Oncol. 2002 May;13(5):807-8
references: 12075754
references: J Clin Oncol. 2001 Oct 15;19(20):4074-80
references: 11600610